| Drug Name |
Betahistine |
| Drug ID |
BADD_D00258 |
| Description |
Ménière's disease is a progressive disease of the inner ear characterized by vertigo, tinnitus, and hearing loss. It has a significant impact on both the physical and social functioning of affected individuals.[A220318,L16408]
Betahistine is a histamine-like antivertigo drug used for treating symptoms associated with Ménière's disease. It is thought to reduce symptoms through its actions on histamine receptors.[A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy. It is currently marketed in Canada by various companies, including Teva Pharmaceuticals. |
| Indications and Usage |
For the reduction of episodes of vertigo association with Ménière's disease. |
| Marketing Status |
Not Available |
| ATC Code |
N07CA01 |
| DrugBank ID |
DB06698
|
| KEGG ID |
D07522
|
| MeSH ID |
D001621
|
| PubChem ID |
2366
|
| TTD Drug ID |
D0XW9U
|
| NDC Product Code |
Not Available |
| Synonyms |
Betahistine | Aequamen | Betahistin-Ratiopharm | Betahistin Ratiopharm | Betahistine Dihydrobromide | Dihydrobromide, Betahistine | Betahistine Hydrochloride | Hydrochloride, Betahistine | Betahistine Dihydrochloride | Dihydrochloride, Betahistine | Betahistine Mesylate | Mesylate, Betahistine | Betahistine Methanesulphonate | Methanesulphonate, Betahistine | Betahistine Methanesulfonate | Methanesulfonate, Betahistine | Betavert | By-Vertin | By Vertin | Extovyl | Fidium | Lectil | Melopat | Mersilon | PT-9 | PT 9 | PT9 | Ribrain | Serc | Betaserc | Vasomotal | Betahistine Biphar | Vertigon | Betahistin AL | Betahistin Stada |
